



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 



## SPARC. Rabbit Antigen Immunoaffinity Purified Polyclonal

Secreted Protein Acidic and Rich in Cysteine, SPARC, SPARC-related modular calcium-binding protein 2 [Precursor], Secreted modular calcium-binding protein 2, SMOC-2, Smooth muscle-associated protein 2, SMAP-2

### BACKGROUND


SPARC is a key factor in cell-matrix interactions and possibly tumour aggressiveness. The SPARC gene, which encodes a multifunctional glycoprotein with roles in tissue development, remodelling and fibrosis. A regulator of cell-extracellular matrix (ECM) interactions, SPARC represents a major factor in the ECM remodelling occurring during tumour invasion. *in silico* analysis reveals 4 UTR-SNPs located in the 3'-UTR of the SPARC gene, corresponding to 1474 g a, 1551 g c, 1922 t g and 2072 c t changes, which are significantly associated with tumoral state of the tissue. Of all hits, the 2072 SPARC polymorphism had the best association with cancer.

SPARC therefore is a gene involved in a number of diseases including rheumatoid arthritis, scleroderma, tumor development and metastasis. SPARC variants have been detected in tumour samples of patients with acute myeloblastic leukemia (AML).

### IMMUNOGEN

Synthetic peptide derived from the human SPARC protein.

Western Blot- Detection of endogenous SPARC in mouse heart lysate using X1867P (0.75 ug/ml) and anti-rabbit HRP (1:75k) and using Pierce's Super Signal West Femto. IHC- Detection of endogenous SPARC in human hepatocellular carcinoma (HCC). 2 ug/ml X1867P, developed with Vector ImmPress anti-rabbit HRP and DAB substrate.



### ORDERING INFORMATION

**CATALOG NUMBER**  
X1867P

**SIZE**  
70 µg  
**FORM**  
Affinity Purified

**HOST/CLONE**  
Rabbit

**FORMULATION**  
Provided as ligand affinity purified antibody in phosphate buffered saline with 0.08% sodium azide

**CONCENTRATION**  
Lot specific, see vial

**ISOTYPE**

**APPLICATIONS**  
Western Blot, Immunohistochemistry, ELISA

**SPECIES REACTIVITY**  
Human SPARC, may cross react with SPARCL1

**ACCESSION NUMBER**  
Human P09486

**POSITIVE CONTROL/TISSUE EXPRESSION**

Antibody has been tested on mouse heart lysate.

**COMMENTS**

Antibody can be used for Western blotting (0.5-1  $\mu$ g/ml). Optimal concentration should be evaluated by serial dilutions.

**PURIFICATION**

Antigen Immunoaffinity Purification

**SHIP CONDITIONS**

Ship on dry ice, freeze upon arrival

**STORAGE CUSTOMER**

Product should be stored at -70°C. Aliquot to avoid freeze/thaw cycles

**STABILITY**

Products are stable for one year from purchase when stored properly

**REFERENCES**

1. Shi Q, et al. 'Targeting SPARC expression decreases glioma cellular survival and invasion associated with reduced activities of FAK and ILK kinases.' *Oncogene*. 2007 Jan 8; [Epub ahead of print] PMID: 17213807
2. Aouacheria A, et al. 'In silico whole-genome screening for cancer-related single-nucleotide polymorphisms located in human mRNA untranslated regions.' *BMC Genomics*. 2007 Jan 3;8(1):2 [Epub ahead of print] PMID: 17201911
3. Xue LY, et al. 'Tissue microarray analysis reveals a tight correlation between protein expression pattern and progression of esophageal squamous cell carcinoma.' *BMC Cancer*. 2006 Dec 22;6(1):296 [Epub ahead of print] PMID: 17187659
4. Arp HP, et al. 'Predicting the partitioning behavior of various highly fluorinated compounds.' *Environ Sci Technol*. 2006 Dec 1;40(23):7298-304. PMID: 17180981
5. Kelly KA, et al. 'SPARC is a VCAM-1 counter-ligand that mediates leukocyte transmigration.' *J Leukoc Biol*. 2006 Dec 18; [Epub ahead of print]
6. Markovic, S., et al. 'Tumor SPARC microenvironment signature (SMS) and plasma levels in a phase II trial of unresectable stage IV melanoma treated with *nab*-paclitaxel and carboplatin: A translational study of NCCTG trial N057E.' *J. Clin. Oncol*. 2010, Vol. 28, No. 15, 8578
7. Weiss, G.J., et al. 'Molecular characterization of interdigitating dendritic cell sarcoma.' *Rare Tumors*, 2010, 2:e50

**PRODUCT SPECIFIC REFERENCES**

1. Kelly, Kimberly A. et al, 'SPARC is a VCAM-1 counter-ligand that mediates leukocyte transmigration' *Journal of Leukocyte Biology* 2007, 81, 3, 748-756